Krystal Biotech, Inc. (KRYS) Tops Q1 EPS by 35c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts KRYS Hot Sheet
Join SI Premium – FREE
Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q1 EPS of $1.83, $0.35 better than the analyst estimate of $1.48. Revenue for the quarter came in at $116.36 million versus the consensus estimate of $111.47 million.
For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dutch Bros Inc. (BROS) Tops Q3 EPS by 1c; offers guidance
- LegalZoom (LZ) Misses Q3 EPS by 1c; Offers Guidance
- Centennial Resource Development, Inc. (PR) Tops Q3 EPS by 9c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
